Elotuzumab (original) (raw)
إلوتوزوماب هو جسم مضاد وحيد النسيلة في المرحلة الثالثة من التجارب السريرية ليستخدم في علاج الورم النقوي المتعدد.
| Property | Value |
|---|---|
| dbo:abstract | إلوتوزوماب هو جسم مضاد وحيد النسيلة في المرحلة الثالثة من التجارب السريرية ليستخدم في علاج الورم النقوي المتعدد. (ar) Elotuzumab ist ein monoklonaler Antikörper und wird als Arzneistoff in der Therapie des multiplen Myeloms bei bestimmten Patienten eingesetzt. (de) Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is done intravenously. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. It is being developed by Bristol Myers Squibb and AbbVie. Common side effects of elotuzumab with lenalidomide and dexamethasone includes fatigue, diarrhea, pyrexia, constipation, cough, peripheral neuropathy, nasopharyngitis, upper respiratory tract infection, decreased appetite, and pneumonia. The most common side effects of elotuzumab with pomalidomide and dexamethasone includes constipation and hyperglycemia. There is no available information for the use of elotuzumab in pregnant women. Elotuzumab is an immunostimulatory antibody that targets the Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) through two mechanisms. In May 2014, it was granted breakthrough therapy designation by the US Food and Drug Administration (FDA) (for multiple myeloma). The initial FDA approval of elotuzumab in 2015 in combination with lenalidomide and dexamethasone was carried out through the results illustrated in the ELOQUENT 2 study. In May 2016 the EC/EU gave a similar approval. Furthermore, the results of the ELOQUENT 3 study led to the FDA approval of elotuzumab in combination with pomalidomide and dexamethasone in 2018. (en) L'elotuzumab o HuLuc63) è un anticorpo monoclonale umanizzato in fase di sperimentazione clinica, per il trattamento delle recidive del mieloma multiplo. Il target molecolare del farmaco è l'antigene SLAM family member 7 (gene SLAMF7) noto anche come . Elotuzumab è stato approvato dalla FDA nel 2015 (con designazione di “breakthrough therapy") per il trattamento del mieloma multiplo (in associazione con lenalidomide+desametasone) e ha ottenuto lo status di "orphan drug". (it) エロツズマブ (Elotuzumab, 製品名 Empliciti / エムプリシティ, ブリストル・マイヤーズスクイブ製造販売)は ヒト化モノクローナル抗体 のひとつであり、 多発性骨髄腫 の治療に用いられる。 薬理作用は に対する抗体で、腫瘍細胞への細胞傷害性である。 (ja) Elotuzumab – lek biologiczny o działaniu immunosupresyjnym, obecnie (2012) w fazie badań klinicznych w terapii szpiczaka mnogiego, przeciwciała monoklonalne skierowane przeciwko receptorowi CS1 występującymi na powierzchni komórek szpiczaka mnogiego, receptory te są reprezentowane w minimalny sposób na innych komórkach organizmu. Badania prowadzone są przez firmy Bristol-Myers Squibb i Abbott. (pl) Элотузумаб — лекарственный препарат, моноклональное антитело для лечения множественной миеломы. Одобрен для применения: США (2015). Наиболее распространенными побочными реакциями (у 20% или выше), отмеченными у пациентов, получавших элотузумаб в исследовании, были: усталость, диарея, запор, кашель, , назофарингит, инфекция верхних дыхательных путей, и пневмония. (ru) |
| dbo:alternativeName | Empliciti (en) |
| dbo:bioavailability | 100.000000 (xsd:float) |
| dbo:casNumber | 915296-00-3 |
| dbo:drugbank | DB06317 |
| dbo:fdaUniiCode | 1351PE5UGS |
| dbo:kegg | D09337 |
| dbo:wikiPageExternalLink | https://druginfo.nlm.nih.gov/drugportal/name/elotuzumab |
| dbo:wikiPageID | 18864393 (xsd:integer) |
| dbo:wikiPageLength | 14123 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1095729800 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Natural_killer_cell dbr:Peripheral_neuropathy dbr:Intravenous_therapy dbr:Cough dbr:Multicenter_trial dbr:Monoclonal_antibody dbr:Multiple_myeloma dbr:Constipation dbr:Open-label_trial dbr:Phase_3_clinical_testing dbr:Lenalidomide dbr:Fatigue dbr:Plasma_cell dbr:Progression-free_survival dbr:Protease_inhibitor_(pharmacology) dbr:Bristol_Myers_Squibb dbr:AbbVie dbr:Acetaminophen dbc:Orphan_drugs dbr:Food_and_Drug_Administration dbr:Breakthrough_therapy dbr:Diarrhea dbr:Glycoprotein dbr:Randomized_controlled_trial dbr:Hematopoietic dbr:Hyperglycemia dbc:AbbVie_brands dbc:Breakthrough_therapy dbc:Bristol_Myers_Squibb dbc:Monoclonal_antibodies_for_tumors dbr:Efficacy dbr:Dexamethasone dbr:Diphenhydramine dbr:Pneumonia dbr:Pomalidomide dbr:Ranitidine dbr:Side_effect dbr:Upper_respiratory_tract_infection dbr:SLAMF7 dbr:Pregnant_women dbr:Control_group dbr:Pyrexia dbr:Nasopharyngitis |
| dbp:atcPrefix | L01 (en) |
| dbp:atcSuffix | FX08 (en) |
| dbp:bioavailability | 100.0 |
| dbp:c | 6476 (xsd:integer) |
| dbp:casNumber | 915296 (xsd:integer) |
| dbp:chemspiderid | none (en) |
| dbp:dailymedid | Elotuzumab (en) |
| dbp:drugbank | DB06317 (en) |
| dbp:h | 9982 (xsd:integer) |
| dbp:iupharLigand | 8361 (xsd:integer) |
| dbp:kegg | D09337 (en) |
| dbp:legalAu | S4 (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:licenceEu | yes (en) |
| dbp:mabType | mab (en) |
| dbp:n | 1714 (xsd:integer) |
| dbp:o | 2016 (xsd:integer) |
| dbp:pregnancyAu | C (en) |
| dbp:routesOfAdministration | dbr:Intravenous_therapy |
| dbp:s | 42 (xsd:integer) |
| dbp:source | zu (en) |
| dbp:synonyms | HuLuc63 (en) |
| dbp:target | dbr:SLAMF7 |
| dbp:tradename | Empliciti (en) |
| dbp:type | mab (en) |
| dbp:unii | 1351 (xsd:integer) |
| dbp:verifiedfields | changed (en) |
| dbp:verifiedrevid | 457123959 (xsd:integer) |
| dbp:watchedfields | changed (en) |
| dbp:wikiPageUsesTemplate | dbt:Cite_web dbt:Drugbox dbt:Portal_bar dbt:Reflist dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Monoclonals_for_tumors |
| dcterms:subject | dbc:Orphan_drugs dbc:AbbVie_brands dbc:Breakthrough_therapy dbc:Bristol_Myers_Squibb dbc:Monoclonal_antibodies_for_tumors |
| gold:hypernym | dbr:Antibody |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:WikicatMonoclonalAntibodiesForTumors yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 umbel-rc:DrugProduct |
| rdfs:comment | إلوتوزوماب هو جسم مضاد وحيد النسيلة في المرحلة الثالثة من التجارب السريرية ليستخدم في علاج الورم النقوي المتعدد. (ar) Elotuzumab ist ein monoklonaler Antikörper und wird als Arzneistoff in der Therapie des multiplen Myeloms bei bestimmten Patienten eingesetzt. (de) L'elotuzumab o HuLuc63) è un anticorpo monoclonale umanizzato in fase di sperimentazione clinica, per il trattamento delle recidive del mieloma multiplo. Il target molecolare del farmaco è l'antigene SLAM family member 7 (gene SLAMF7) noto anche come . Elotuzumab è stato approvato dalla FDA nel 2015 (con designazione di “breakthrough therapy") per il trattamento del mieloma multiplo (in associazione con lenalidomide+desametasone) e ha ottenuto lo status di "orphan drug". (it) エロツズマブ (Elotuzumab, 製品名 Empliciti / エムプリシティ, ブリストル・マイヤーズスクイブ製造販売)は ヒト化モノクローナル抗体 のひとつであり、 多発性骨髄腫 の治療に用いられる。 薬理作用は に対する抗体で、腫瘍細胞への細胞傷害性である。 (ja) Elotuzumab – lek biologiczny o działaniu immunosupresyjnym, obecnie (2012) w fazie badań klinicznych w terapii szpiczaka mnogiego, przeciwciała monoklonalne skierowane przeciwko receptorowi CS1 występującymi na powierzchni komórek szpiczaka mnogiego, receptory te są reprezentowane w minimalny sposób na innych komórkach organizmu. Badania prowadzone są przez firmy Bristol-Myers Squibb i Abbott. (pl) Элотузумаб — лекарственный препарат, моноклональное антитело для лечения множественной миеломы. Одобрен для применения: США (2015). Наиболее распространенными побочными реакциями (у 20% или выше), отмеченными у пациентов, получавших элотузумаб в исследовании, были: усталость, диарея, запор, кашель, , назофарингит, инфекция верхних дыхательных путей, и пневмония. (ru) Elotuzumab, sold under the brand name Empliciti, is a humanized IgG1 monoclonal antibody medication used in combination with lenalidomide and dexamethasone, for adults that have received 1 to 3 prior therapies for the treatment of multiple myeloma. It is also indicated for adult patients in combination with pomalidomide and dexamethasone, who have received 2 prior therapies including lenalidomide and a protease inhibitor. Administration of elotuzumab is done intravenously. Each intravenous injection of elotuzumab should be premedicated with dexamethasone, diphenhydramine, ranitidine and acetaminophen. It is being developed by Bristol Myers Squibb and AbbVie. (en) |
| rdfs:label | إلوتوزوماب (ar) Elotuzumab (en) Elotuzumab (de) Elotuzumab (it) エロツズマブ (ja) Elotuzumab (pl) Элотузумаб (ru) |
| owl:sameAs | freebase:Elotuzumab yago-res:Elotuzumab wikidata:Elotuzumab dbpedia-ar:Elotuzumab dbpedia-de:Elotuzumab dbpedia-it:Elotuzumab dbpedia-ja:Elotuzumab dbpedia-pl:Elotuzumab dbpedia-ru:Elotuzumab https://global.dbpedia.org/id/3SZoB |
| prov:wasDerivedFrom | wikipedia-en:Elotuzumab?oldid=1095729800&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Elotuzumab |
| is dbo:wikiPageRedirects of | dbr:Empliciti |
| is dbo:wikiPageWikiLink of | dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:Multiple_myeloma dbr:Monoclonal_antibody_therapy dbr:Bristol_Myers_Squibb dbr:Filanesib dbr:Cardiac_amyloidosis dbr:ATC_code_L01 dbr:Empliciti dbr:Cancer_immunotherapy dbr:Signaling_lymphocytic_activation_molecule dbr:List_of_therapeutic_monoclonal_antibodies dbr:SLAMF7 dbr:List_of_drugs:_E–El |
| is foaf:primaryTopic of | wikipedia-en:Elotuzumab |